{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T15:43:11Z","timestamp":1788622991332,"version":"build-2803163510"},"reference-count":104,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006470","name":"Aristotle University of Thessaloniki","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006470","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Obes Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose of Review<\/jats:title>\n                    <jats:p>Growth hormone (GH) deficiency (GHD) in adults presents with metabolic syndrome features, such as abdominal obesity, dysglycemia, atherogenic dyslipidemia and hypertension, which are closely associated with metabolic dysfunction-associated steatotic liver disease (MASLD). This narrative review aims to critically summarize the available data on the link between adult GHD and MASLD, focusing on possible pathophysiological mechanisms, clinical associations and treatment considerations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent Findings<\/jats:title>\n                    <jats:p>Experimental evidence supports a direct effect of GH on hepatocytes predominantly through the Janus kinase 2 (JAK2)\u2013signal transducer and activator of transcription 5 (STAT5) pathway, which reduces hepatic steatosis. Hepatic steatosis in GHD may also be indirectly affected through the unfavorable effects of GHD on insulin resistance and metabolic syndrome features. Limited data show that low insulin-like growth factor-1 (IGF-1) concentrations may contribute to hepatic fibrosis by acting on hepatic stellate cells. Regarding clinical associations, MASLD is highly prevalent in adults with GHD, and, vice versa, lower or similar circulating GH\/IGF-1 concentrations are reported in patients with MASLD compared with those without MASLD. Regarding treatment, favorable effects of recombinant GH (rhGH) on hepatic steatosis and, possibly, on hepatic fibrosis progression in patients with MASLD and GHD or with low IGF-1 concentrations have been demonstrated in interventional studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Existing findings may warrant more specifically designed studies to carefully assess the risk\u2013benefit ratio of rhGH replacement in adults with GHD and MASLD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s13679-026-00692-w","type":"journal-article","created":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T01:59:12Z","timestamp":1771466352000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Adult Growth Hormone Deficiency and Metabolic Dysfunction-Associated Steatotic Liver Disease"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9232-4042","authenticated-orcid":false,"given":"Stergios A.","family":"Polyzos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7271-6329","authenticated-orcid":false,"given":"Alessandro","family":"Mantovani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4325-3900","authenticated-orcid":false,"given":"Giovanni","family":"Targher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,19]]},"reference":[{"key":"692_CR1","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1056\/NEJMra2412865","volume":"393","author":"G Targher","year":"2025","unstructured":"Targher G, Valenti L, Byrne CD. Metabolic dysfunction-associated steatotic liver disease. N Engl J Med. 2025;393:683\u201398. https:\/\/doi.org\/10.1056\/NEJMra2412865.","journal-title":"N Engl J Med"},{"key":"692_CR2","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1111\/dom.16117","volume":"27","author":"SA Polyzos","year":"2025","unstructured":"Polyzos SA, Targher G. Hepatic thyroid hormone receptor-\u03b2 signalling: mechanisms and recent advancements in the treatment of metabolic dysfunction-associated steatohepatitis. Diabetes Obes Metab. 2025;27:1635\u201347. https:\/\/doi.org\/10.1111\/dom.16117.","journal-title":"Diabetes Obes Metab"},{"key":"692_CR3","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.arcmed.2020.11.010","volume":"52","author":"E Makri","year":"2021","unstructured":"Makri E, Goulas A, Polyzos SA. Epidemiology, pathogenesis, diagnosis and emerging treatment of nonalcoholic fatty liver disease. Arch Med Res. 2021;52:25\u201337. https:\/\/doi.org\/10.1016\/j.arcmed.2020.11.010.","journal-title":"Arch Med Res"},{"key":"692_CR4","first-page":"127","volume":"13","author":"SA Polyzos","year":"2009","unstructured":"Polyzos SA, Kountouras J, Zavos C. The multi-hit process and the antagonistic roles of tumor necrosis factor-alpha and adiponectin in nonalcoholic fatty liver disease. Hippokratia. 2009;13:127.","journal-title":"Hippokratia"},{"key":"692_CR5","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.3390\/jpm12071166","volume":"12","author":"ES Makri","year":"2022","unstructured":"Makri ES, Makri E, Polyzos SA. Combination therapies for nonalcoholic fatty liver disease. J Pers Med. 2022;12:1166. https:\/\/doi.org\/10.3390\/jpm12071166.","journal-title":"J Pers Med"},{"key":"692_CR6","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","volume":"79","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multi-society Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023;79:1542\u201356. https:\/\/doi.org\/10.1016\/j.jhep.2023.06.003.","journal-title":"J Hepatol"},{"key":"692_CR7","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1097\/MCG.0b013e31824587e0","volume":"46","author":"SA Polyzos","year":"2012","unstructured":"Polyzos SA, Kountouras J, Zavos C, Deretzi G. Nonalcoholic fatty liver disease: multimodal treatment options for a pathogenetically multiple-hit disease. J Clin Gastroenterol. 2012;46:272\u201384. https:\/\/doi.org\/10.1097\/MCG.0b013e31824587e0.","journal-title":"J Clin Gastroenterol"},{"key":"692_CR8","doi-asserted-by":"publisher","first-page":"89","DOI":"10.23736\/S0391-1977.16.02576-1","volume":"42","author":"SA Polyzos","year":"2017","unstructured":"Polyzos SA. Endocrine and metabolic disorders interplaying with non-alcoholic fatty liver disease. Minerva Endocrinol. 2017;42:89\u201391. https:\/\/doi.org\/10.23736\/S0391-1977.16.02576-1.","journal-title":"Minerva Endocrinol"},{"key":"692_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2011.00032","volume":"2","author":"A Vijayakumar","year":"2011","unstructured":"Vijayakumar A, Yakar S, Leroith D. The intricate role of growth hormone in metabolism. Front Endocrinol (Lausanne). 2011;2:32. https:\/\/doi.org\/10.3389\/fendo.2011.00032.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"692_CR10","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.4158\/gl-2019-0405","volume":"25","author":"KCJ Yuen","year":"2019","unstructured":"Yuen KCJ, Biller BMK, Radovick S, Carmichael JD, Jasim S, Pantalone KM, et al. American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of growth hormone deficiency in adults and patients transitioning from pediatric to adult care. Endocr Pract. 2019;25:1191\u2013232. https:\/\/doi.org\/10.4158\/gl-2019-0405.","journal-title":"Endocr Pract"},{"key":"692_CR11","doi-asserted-by":"publisher","first-page":"2551","DOI":"10.1056\/NEJMra1817346","volume":"380","author":"S Melmed","year":"2019","unstructured":"Melmed S. Pathogenesis and diagnosis of growth hormone deficiency in adults. N Engl J Med. 2019;380:2551\u201362. https:\/\/doi.org\/10.1056\/NEJMra1817346.","journal-title":"N Engl J Med"},{"key":"692_CR12","first-page":"41","volume":"22","author":"G Johannsson","year":"1999","unstructured":"Johannsson G, Bengtsson BA. Growth hormone and the metabolic syndrome. J Endocrinol Invest. 1999;22:41\u20136.","journal-title":"J Endocrinol Invest"},{"key":"692_CR13","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1530\/eje-11-0599","volume":"165","author":"J Verhelst","year":"2011","unstructured":"Verhelst J, Mattsson AF, Luger A, Thunander M, G\u00f3th MI, Koltowska-H\u00e4ggstr\u00f6m M, et al. Prevalence and characteristics of the metabolic syndrome in 2479 hypopituitary patients with adult-onset GH deficiency before GH replacement: a KIMS analysis. Eur J Endocrinol. 2011;165:881\u20139. https:\/\/doi.org\/10.1530\/eje-11-0599.","journal-title":"Eur J Endocrinol"},{"key":"692_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0044136","volume":"7","author":"L Xu","year":"2012","unstructured":"Xu L, Xu C, Yu C, Miao M, Zhang X, Zhu Z, et al. Association between serum growth hormone levels and nonalcoholic fatty liver disease: a cross-sectional study. PLoS One. 2012;7:e44136. https:\/\/doi.org\/10.1371\/journal.pone.0044136.","journal-title":"PLoS One"},{"key":"692_CR15","doi-asserted-by":"publisher","first-page":"299","DOI":"10.2174\/156652409787847191","volume":"72","author":"SA Polyzos","year":"2009","unstructured":"Polyzos SA, Kountouras J, Zavos C. Nonalcoholic fatty liver disease: the pathogenetic roles of insulin resistance and adipocytokines. Curr Mol Med. 2009;72:299\u2013314. https:\/\/doi.org\/10.2174\/156652409787847191.","journal-title":"Curr Mol Med"},{"key":"692_CR16","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.bbrc.2012.05.115","volume":"423","author":"H Nishizawa","year":"2012","unstructured":"Nishizawa H, Takahashi M, Fukuoka H, Iguchi G, Kitazawa R, Takahashi Y. GH-independent IGF-I action is essential to prevent the development of nonalcoholic steatohepatitis in a GH-deficient rat model. Biochem Biophys Res Commun. 2012;423:295\u2013300. https:\/\/doi.org\/10.1016\/j.bbrc.2012.05.115.","journal-title":"Biochem Biophys Res Commun"},{"key":"692_CR17","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1507\/endocrj.EJ23-0157","volume":"70","author":"T Kong","year":"2023","unstructured":"Kong T, Gu Y, Sun L, Zhou R, Li J, Shi J. Association of nonalcoholic fatty liver disease and growth hormone deficiency: a systematic review and meta-analysis. Endocr J. 2023;70:959\u201367. https:\/\/doi.org\/10.1507\/endocrj.EJ23-0157.","journal-title":"Endocr J"},{"issue":"Suppl 1","key":"692_CR18","doi-asserted-by":"publisher","first-page":"S41","DOI":"10.1530\/eje-09-0291","volume":"161","author":"J Verhelst","year":"2009","unstructured":"Verhelst J, Abs R. Cardiovascular risk factors in hypopituitary GH-deficient adults. Eur J Endocrinol. 2009;161(Suppl 1):S41\u20139. https:\/\/doi.org\/10.1530\/eje-09-0291.","journal-title":"Eur J Endocrinol"},{"key":"692_CR19","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1056\/nejm198506063122302","volume":"312","author":"PJ Campbell","year":"1985","unstructured":"Campbell PJ, Bolli GB, Cryer PE, Gerich JE. Pathogenesis of the dawn phenomenon in patients with insulin-dependent diabetes mellitus. Accelerated glucose production and impaired glucose utilization due to nocturnal surges in growth hormone secretion. N Engl J Med. 1985;312:1473\u20139. https:\/\/doi.org\/10.1056\/nejm198506063122302.","journal-title":"N Engl J Med"},{"key":"692_CR20","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.beem.2013.05.003","volume":"27","author":"FR Sattler","year":"2013","unstructured":"Sattler FR. Growth hormone in the aging male. Best Pract Res Clin Endocrinol Metab. 2013;27:541\u201355. https:\/\/doi.org\/10.1016\/j.beem.2013.05.003.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"692_CR21","doi-asserted-by":"publisher","first-page":"424","DOI":"10.2337\/diab.41.4.424","volume":"41","author":"DA Fryburg","year":"1992","unstructured":"Fryburg DA, Louard RJ, Gerow KE, Gelfand RA, Barrett EJ. Growth hormone stimulates skeletal muscle protein synthesis and antagonizes insulin\u2019s antiproteolytic action in humans. Diabetes. 1992;41:424\u20139. https:\/\/doi.org\/10.2337\/diab.41.4.424.","journal-title":"Diabetes"},{"key":"692_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2020.111038","volume":"518","author":"R Sharma","year":"2020","unstructured":"Sharma R, Kopchick JJ, Puri V, Sharma VM. Effect of growth hormone on insulin signaling. Mol Cell Endocrinol. 2020;518:111038. https:\/\/doi.org\/10.1016\/j.mce.2020.111038.","journal-title":"Mol Cell Endocrinol"},{"key":"692_CR23","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1111\/j.1365-2265.1992.tb02347.x","volume":"37","author":"RC Cuneo","year":"1992","unstructured":"Cuneo RC, Salomon F, McGauley GA, S\u00f6nksen PH. The growth hormone deficiency syndrome in adults. Clin Endocrinol (Oxf). 1992;37:387\u201397. https:\/\/doi.org\/10.1111\/j.1365-2265.1992.tb02347.x.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"692_CR24","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1210\/jc.2013-2394","volume":"99","author":"C Gazzaruso","year":"2014","unstructured":"Gazzaruso C, Gola M, Karamouzis I, Giubbini R, Giustina A. Cardiovascular risk in adult patients with growth hormone (GH) deficiency and following substitution with GH\u2013an update. J Clin Endocrinol Metab. 2014;99:18\u201329. https:\/\/doi.org\/10.1210\/jc.2013-2394.","journal-title":"J Clin Endocrinol Metab"},{"key":"692_CR25","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1056\/NEJMra2409076","volume":"393","author":"A Giustina","year":"2025","unstructured":"Giustina A, Colao A. Acromegaly. N Engl J Med. 2025;393:1926\u201339. https:\/\/doi.org\/10.1056\/NEJMra2409076.","journal-title":"N Engl J Med"},{"key":"692_CR26","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1038\/s41574-024-01037-0","volume":"21","author":"RD Kineman","year":"2025","unstructured":"Kineman RD, Del Rio-Moreno M, Waxman DJ. Liver-specific actions of GH and IGF1 that protect against MASLD. Nat Rev Endocrinol. 2025;21:105\u201317. https:\/\/doi.org\/10.1038\/s41574-024-01037-0.","journal-title":"Nat Rev Endocrinol"},{"key":"692_CR27","doi-asserted-by":"publisher","first-page":"19937","DOI":"10.1074\/jbc.M109.014308","volume":"284","author":"Y Fan","year":"2009","unstructured":"Fan Y, Menon RK, Cohen P, Hwang D, Clemens T, DiGirolamo DJ. Liver-specific deletion of the growth hormone receptor reveals essential role of growth hormone signaling in hepatic lipid metabolism. J Biol Chem. 2009;284:19937\u201344. https:\/\/doi.org\/10.1074\/jbc.M109.014308.","journal-title":"J Biol Chem"},{"key":"692_CR28","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1210\/en.2010-0537","volume":"152","author":"JL Barclay","year":"2011","unstructured":"Barclay JL, Nelson CN, Ishikawa M, Murray LA, Kerr LM, McPhee TR, et al. GH-dependent STAT5 signaling plays an important role in hepatic lipid metabolism. Endocrinology. 2011;152:181\u201392. https:\/\/doi.org\/10.1210\/en.2010-0537.","journal-title":"Endocrinology"},{"key":"692_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2023.155589","volume":"144","author":"MC V\u00e1zquez-Borrego","year":"2023","unstructured":"V\u00e1zquez-Borrego MC, Del R\u00edo-Moreno M, Pyatkov M, Sarmento-Cabral A, Mahmood M, Pelke N. Direct and systemic actions of growth hormone receptor (GHR)-signaling on hepatic glycolysis, de novo lipogenesis and insulin sensitivity, associated with steatosis. Metabolism. 2023;144:155589. https:\/\/doi.org\/10.1016\/j.metabol.2023.155589.","journal-title":"Metabolism"},{"key":"692_CR30","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1172\/jci42894","volume":"121","author":"BC Sos","year":"2011","unstructured":"Sos BC, Harris C, Nordstrom SM, Tran JL, Bal\u00e1zs M, Caplazi P. Abrogation of growth hormone secretion rescues fatty liver in mice with hepatocyte-specific deletion of JAK2. J Clin Invest. 2011;121:1412\u201323. https:\/\/doi.org\/10.1172\/jci42894.","journal-title":"J Clin Invest"},{"key":"692_CR31","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1002\/hep.21713","volume":"46","author":"Y Cui","year":"2007","unstructured":"Cui Y, Hosui A, Sun R, Shen K, Gavrilova O, Chen W. Loss of signal transducer and activator of transcription 5 leads to hepatosteatosis and impaired liver regeneration\u2020. Hepatology. 2007;46:504\u201313. https:\/\/doi.org\/10.1002\/hep.21713.","journal-title":"Hepatology"},{"key":"692_CR32","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1210\/en.2010-0953","volume":"152","author":"C Tateno","year":"2011","unstructured":"Tateno C, Kataoka M, Utoh R, Tachibana A, Itamoto T, Asahara T. Growth hormone-dependent pathogenesis of human hepatic steatosis in a novel mouse model bearing a human hepatocyte-repopulated liver. Endocrinology. 2011;152:1479\u201391. https:\/\/doi.org\/10.1210\/en.2010-0953.","journal-title":"Endocrinology"},{"key":"692_CR33","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1002\/hep.24509","volume":"54","author":"KM Mueller","year":"2011","unstructured":"Mueller KM, Kornfeld JW, Friedbichler K, Blaas L, Egger G, Esterbauer H, et al. Impairment of hepatic growth hormone and glucocorticoid receptor signaling causes steatosis and hepatocellular carcinoma in mice. Hepatology. 2011;54:1398\u2013409. https:\/\/doi.org\/10.1002\/hep.24509.","journal-title":"Hepatology"},{"key":"692_CR34","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1210\/en.2013-2086","volume":"155","author":"EO List","year":"2014","unstructured":"List EO, Berryman DE, Funk K, Jara A, Kelder B, Wang F, et al. Liver-specific GH receptor gene-disrupted (LiGHRKO) mice have decreased endocrine IGF-I, increased local IGF-I, and altered body size, body composition, and adipokine profiles. Endocrinology. 2014;155:1793\u2013805. https:\/\/doi.org\/10.1210\/en.2013-2086.","journal-title":"Endocrinology"},{"key":"692_CR35","doi-asserted-by":"publisher","first-page":"3598","DOI":"10.2337\/db16-0649","volume":"65","author":"Z Liu","year":"2016","unstructured":"Liu Z, Cordoba-Chacon J, Kineman RD, Cronstein BN, Muzumdar R, Gong Z, et al. Growth hormone control of hepatic lipid metabolism. Diabetes. 2016;65:3598\u2013609. https:\/\/doi.org\/10.2337\/db16-0649.","journal-title":"Diabetes"},{"key":"692_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1371444","volume":"15","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Chen P, Fang X. Proteomic and metabolomic analysis of GH deficiency-induced NAFLD in hypopituitarism: insights into oxidative stress. Front Endocrinol (Lausanne). 2024;15:1371444. https:\/\/doi.org\/10.3389\/fendo.2024.1371444.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"692_CR37","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1136\/gut.2003.024505","volume":"54","author":"S Sanz","year":"2005","unstructured":"Sanz S, Pucilowska JB, Liu S, Rodr\u00edguez-Ortigosa CM, Lund PK, Brenner DA, et al. Expression of insulin-like growth factor I by activated hepatic stellate cells reduces fibrogenesis and enhances regeneration after liver injury. Gut. 2005;54:134\u201341. https:\/\/doi.org\/10.1136\/gut.2003.024505.","journal-title":"Gut"},{"key":"692_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/srep34605","volume":"6","author":"H Nishizawa","year":"2016","unstructured":"Nishizawa H, Iguchi G, Fukuoka H, Takahashi M, Suda K, Bando H, et al. IGF-I induces senescence of hepatic stellate cells and limits fibrosis in a p53-dependent manner. Sci Rep. 2016;6:34605. https:\/\/doi.org\/10.1038\/srep34605.","journal-title":"Sci Rep"},{"key":"692_CR39","doi-asserted-by":"publisher","first-page":"10277","DOI":"10.1074\/jbc.M111.317453","volume":"287","author":"SY Shi","year":"2012","unstructured":"Shi SY, Martin RG, Duncan RE, Choi D, Lu SY, Schroer SA, et al. Hepatocyte-specific deletion of Janus kinase 2 (JAK2) protects against diet-induced steatohepatitis and glucose intolerance. J Biol Chem. 2012;287:10277\u201388. https:\/\/doi.org\/10.1074\/jbc.M111.317453.","journal-title":"J Biol Chem"},{"key":"692_CR40","doi-asserted-by":"publisher","first-page":"15725","DOI":"10.1074\/jbc.M113.460212","volume":"288","author":"C Lu","year":"2013","unstructured":"Lu C, Kumar PA, Sun J, Aggarwal A, Fan Y, Sperling MA, et al. Targeted deletion of growth hormone (GH) receptor in macrophage reveals novel osteopontin-mediated effects of GH on glucose homeostasis and insulin sensitivity in diet-induced obesity. J Biol Chem. 2013;288:15725\u201335. https:\/\/doi.org\/10.1074\/jbc.M113.460212.","journal-title":"J Biol Chem"},{"key":"692_CR41","doi-asserted-by":"publisher","first-page":"776","DOI":"10.4049\/jimmunol.1901330","volume":"205","author":"B Soler Palacios","year":"2020","unstructured":"Soler Palacios B, Nieto C, Fajardo P, de la Gonz\u00e1lez Aleja A, Andr\u00e9s N, Dominguez-Soto \u00c1, et al. Growth hormone reprograms macrophages toward an anti-inflammatory and reparative profile in an MAFB-dependent manner. J Immunol. 2020;205:776\u201388. https:\/\/doi.org\/10.4049\/jimmunol.1901330.","journal-title":"J Immunol"},{"key":"692_CR42","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.celrep.2017.03.046","volume":"19","author":"O Spadaro","year":"2017","unstructured":"Spadaro O, Camell CD, Bosurgi L, Nguyen KY, Youm YH, Rothlin CV, et al. IGF1 shapes macrophage activation in response to immunometabolic challenge. Cell Rep. 2017;19:225\u201334. https:\/\/doi.org\/10.1016\/j.celrep.2017.03.046.","journal-title":"Cell Rep"},{"key":"692_CR43","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1007\/s11102-022-01282-4","volume":"25","author":"L Das","year":"2022","unstructured":"Das L, Sahoo J, Dahiya N, Taneja S, Bhadada SK, Bhat MH, et al. Long-term hepatic and cardiac health in patients diagnosed with Sheehan\u2019s syndrome. Pituitary. 2022;25:971\u201381. https:\/\/doi.org\/10.1007\/s11102-022-01282-4.","journal-title":"Pituitary"},{"key":"692_CR44","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1530\/ec-14-0078","volume":"3","author":"RD Diniz","year":"2014","unstructured":"Diniz RD, Souza RM, Salvatori R, Franca A, Gomes-Santos E, Ferr\u00e3o TO, et al. Liver status in congenital, untreated, isolated GH deficiency. Endocr Connect. 2014;3:132\u20137. https:\/\/doi.org\/10.1530\/ec-14-0078.","journal-title":"Endocr Connect"},{"key":"692_CR45","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1530\/eje-12-0002","volume":"166","author":"CJ Gardner","year":"2012","unstructured":"Gardner CJ, Irwin AJ, Daousi C, McFarlane IA, Joseph F, Bell JD, et al. Hepatic steatosis, GH deficiency and the effects of GH replacement: a Liverpool magnetic resonance spectroscopy study. Eur J Endocrinol. 2012;166:993\u20131002. https:\/\/doi.org\/10.1530\/eje-12-0002.","journal-title":"Eur J Endocrinol"},{"key":"692_CR46","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1055\/s-0030-1265217","volume":"43","author":"JW Hong","year":"2011","unstructured":"Hong JW, Kim JY, Kim YE, Lee EJ. Metabolic parameters and nonalcoholic fatty liver disease in hypopituitary men. Horm Metab Res. 2011;43:48\u201354. https:\/\/doi.org\/10.1055\/s-0030-1265217.","journal-title":"Horm Metab Res"},{"key":"692_CR47","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1057769","volume":"13","author":"YA Hwang","year":"2023","unstructured":"Hwang YA, Lee HW, Ahn SH, Lee EJ, Ku CR, Kim SU. Positive association between nonalcoholic fatty liver disease and growth hormone deficiency in patients with nonfunctioning pituitary adenoma. Front Endocrinol (Lausanne). 2023;13:1057769. https:\/\/doi.org\/10.3389\/fendo.2022.1057769.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"692_CR48","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1136\/gut.52.6.914","volume":"52","author":"T Ichikawa","year":"2003","unstructured":"Ichikawa T, Hamasaki K, Ishikawa H, Ejima E, Eguchi K, Nakao K. Non-alcoholic steatohepatitis and hepatic steatosis in patients with adult onset growth hormone deficiency. Gut. 2003;52:914. https:\/\/doi.org\/10.1136\/gut.52.6.914.","journal-title":"Gut"},{"key":"692_CR49","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/j.eprac.2021.06.003","volume":"27","author":"SJ Kang","year":"2021","unstructured":"Kang SJ, Kwon A, Jung MK, Chae HW, Kim S, Koh H, et al. High prevalence of nonalcoholic fatty liver disease among adolescents and young adults with hypopituitarism due to growth hormone deficiency. Endocr Pract. 2021;27:1149\u201355. https:\/\/doi.org\/10.1016\/j.eprac.2021.06.003.","journal-title":"Endocr Pract"},{"key":"692_CR50","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/cen.13042","volume":"85","author":"F Meienberg","year":"2016","unstructured":"Meienberg F, Yee M, Johnston D, Cox J, Robinson S, Bell JD, et al. Liver fat in adults with GH deficiency: comparison to matched controls and the effect of GH replacement. Clin Endocrinol (Oxf). 2016;85:76\u201384. https:\/\/doi.org\/10.1111\/cen.13042.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"692_CR51","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1530\/eje-12-0252","volume":"167","author":"H Nishizawa","year":"2012","unstructured":"Nishizawa H, Iguchi G, Murawaki A, Fukuoka H, Hayashi Y, Kaji H, et al. Nonalcoholic fatty liver disease in adult hypopituitary patients with GH deficiency and the impact of GH replacement therapy. Eur J Endocrinol. 2012;167:67\u201374. https:\/\/doi.org\/10.1530\/eje-12-0252.","journal-title":"Eur J Endocrinol"},{"key":"692_CR52","doi-asserted-by":"publisher","first-page":"E1640","DOI":"10.1210\/jc.2011-1227","volume":"96","author":"F Arturi","year":"2011","unstructured":"Arturi F, Succurro E, Procopio C, Pedace E, Mannino GC, Lugar\u00e0 M, et al. Nonalcoholic fatty liver disease is associated with low Circulating levels of insulin-like growth factor-I. J Clin Endocrinol Metab. 2011;96:E1640\u20134. https:\/\/doi.org\/10.1210\/jc.2011-1227.","journal-title":"J Clin Endocrinol Metab"},{"key":"692_CR53","doi-asserted-by":"publisher","first-page":"473","DOI":"10.2169\/internalmedicine.56.7626","volume":"56","author":"S Chishima","year":"2017","unstructured":"Chishima S, Kogiso T, Matsushita N, Hashimoto E, Tokushige K. The relationship between the growth hormone\/insulin-like growth factor system and the histological features of nonalcoholic fatty liver disease. Intern Med. 2017;56:473\u201380. https:\/\/doi.org\/10.2169\/internalmedicine.56.7626.","journal-title":"Intern Med"},{"key":"692_CR54","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1097\/MEG.0b013e32834e8041","volume":"24","author":"Y Colak","year":"2012","unstructured":"Colak Y, Senates E, Ozturk O, Yilmaz Y, Zemheri E, Yilmaz Enc F, et al. Serum concentrations of human insulin-like growth factor-1 and levels of insulin-like growth factor-binding protein-5 in patients with nonalcoholic fatty liver disease: association with liver histology. Eur J Gastroenterol Hepatol. 2012;24:255\u201361. https:\/\/doi.org\/10.1097\/MEG.0b013e32834e8041.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"692_CR55","doi-asserted-by":"publisher","DOI":"10.1038\/ctg.2016.72","volume":"8","author":"LE Dichtel","year":"2017","unstructured":"Dichtel LE, Corey KE, Misdraji J, Bredella MA, Schorr M, Osganian SA, et al. The association between IGF-1 levels and the histologic severity of nonalcoholic fatty liver disease. Clin Transl Gastroenterol. 2017;8:e217. https:\/\/doi.org\/10.1038\/ctg.2016.72.","journal-title":"Clin Transl Gastroenterol"},{"key":"692_CR56","doi-asserted-by":"publisher","first-page":"e989","DOI":"10.1210\/clinem\/dgad206","volume":"108","author":"P Fellinger","year":"2023","unstructured":"Fellinger P, Beiglb\u00f6ck H, Semmler G, Pfleger L, Smajis S, Baumgartner C, et al. Increased GH\/IGF-I axis activity relates to lower hepatic lipids and phosphor metabolism. J Clin Endocrinol Metab. 2023;108:e989\u201397. https:\/\/doi.org\/10.1210\/clinem\/dgad206.","journal-title":"J Clin Endocrinol Metab"},{"key":"692_CR57","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1111\/j.1365-2265.2011.04291.x","volume":"77","author":"A Fusco","year":"2012","unstructured":"Fusco A, Miele L, D\u2019Uonnolo A, Forgione A, Riccardi L, Cefalo C, et al. Nonalcoholic fatty liver disease is associated with increased GHBP and reduced GH\/IGF-I levels. Clin Endocrinol (Oxf). 2012;77:531\u20136. https:\/\/doi.org\/10.1111\/j.1365-2265.2011.04291.x.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"692_CR58","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s11695-007-9087-1","volume":"17","author":"D Garc\u00eda-Galiano","year":"2007","unstructured":"Garc\u00eda-Galiano D, S\u00e1nchez-Garrido MA, Espejo I, Montero JL, Cost\u00e1n G, Marchal T, et al. IL-6 and IGF-1 are independent prognostic factors of liver steatosis and non-alcoholic steatohepatitis in morbidly obese patients. Obes Surg. 2007;17:493\u2013503. https:\/\/doi.org\/10.1007\/s11695-007-9087-1.","journal-title":"Obes Surg"},{"key":"692_CR59","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1111\/cen.14732","volume":"97","author":"Q Huang","year":"2022","unstructured":"Huang Q, Xu H, Wang X, Mao J, Yu B, Zhu Y, et al. Relationship between growth hormone deficiency and nonalcoholic fatty liver disease in patients with pituitary stalk interruption syndrome. Clin Endocrinol (Oxf). 2022;97:612\u201321. https:\/\/doi.org\/10.1111\/cen.14732.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"692_CR60","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s12072-007-9007-4","volume":"1","author":"T Ichikawa","year":"2007","unstructured":"Ichikawa T, Nakao K, Hamasaki K, Furukawa R, Tsuruta S, Ueda Y, et al. Role of growth hormone, insulin-like growth factor 1 and insulin-like growth factor-binding protein 3 in development of non-alcoholic fatty liver disease. Hepatol Int. 2007;1:287\u201394. https:\/\/doi.org\/10.1007\/s12072-007-9007-4.","journal-title":"Hepatol Int"},{"key":"692_CR61","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1111\/j.1478-3231.2011.02637.x","volume":"32","author":"E Koehler","year":"2012","unstructured":"Koehler E, Swain J, Sanderson S, Krishnan A, Watt K, Charlton M. Growth hormone, dehydroepiandrosterone and adiponectin levels in non-alcoholic steatohepatitis: an endocrine signature for advanced fibrosis in obese patients. Liver Int. 2012;32:279\u201386.","journal-title":"Liver Int"},{"key":"692_CR62","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1111\/j.1572-0241.2002.05641.x","volume":"97","author":"A Lonardo","year":"2002","unstructured":"Lonardo A, Loria P, Leonardi F, Ganazzi D, Carulli N. Growth hormone plasma levels in nonalcoholic fatty liver disease. Am J Gastroenterol. 2002;97:1071\u20132. https:\/\/doi.org\/10.1111\/j.1572-0241.2002.05641.x.","journal-title":"Am J Gastroenterol"},{"key":"692_CR63","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.ghir.2018.01.003","volume":"40","author":"R Matsumoto","year":"2018","unstructured":"Matsumoto R, Koga M, Kasayama S, Fukuoka H, Iguchi G, Odake Y, et al. Factors correlated with serum insulin-like growth factor-I levels in health check-up subjects. Growth Horm IGF Res. 2018;40:55\u201360. https:\/\/doi.org\/10.1016\/j.ghir.2018.01.003.","journal-title":"Growth Horm IGF Res"},{"key":"692_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/j.ghir.2022.101482","volume":"65","author":"SA Osganian","year":"2022","unstructured":"Osganian SA, Subudhi S, Masia R, Drescher HK, Bartsch LM, Chicote ML, et al. Expression of IGF-1 receptor and GH receptor in hepatic tissue of patients with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Growth Horm IGF Res. 2022;65:101482. https:\/\/doi.org\/10.1016\/j.ghir.2022.101482.","journal-title":"Growth Horm IGF Res"},{"key":"692_CR65","doi-asserted-by":"publisher","first-page":"e390","DOI":"10.1210\/clinem\/dgz172","volume":"105","author":"SA Polyzos","year":"2020","unstructured":"Polyzos SA, Perakakis N, Boutari C, Kountouras J, Ghaly W, Anastasilakis AD, et al. Targeted analysis of three hormonal systems identifies molecules associated with the presence and severity of NAFLD. J Clin Endocrinol Metab. 2020;105:e390\u2013400. https:\/\/doi.org\/10.1210\/clinem\/dgz172.","journal-title":"J Clin Endocrinol Metab"},{"key":"692_CR66","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1007\/s12072-018-9893-7","volume":"12","author":"K Rufinatscha","year":"2018","unstructured":"Rufinatscha K, Ress C, Folie S, Haas S, Salzmann K, Moser P, et al. Metabolic effects of reduced growth hormone action in fatty liver disease. Hepatol Int. 2018;12:474\u201381. https:\/\/doi.org\/10.1007\/s12072-018-9893-7.","journal-title":"Hepatol Int"},{"key":"692_CR67","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-9-136","volume":"9","author":"S Savastano","year":"2011","unstructured":"Savastano S, Di Somma C, Pizza G, De Rosa A, Nedi V, Rossi A, et al. Liver-spleen axis, insulin-like growth factor-(IGF)-I axis and fat mass in overweight\/obese females. J Transl Med. 2011;9:136. https:\/\/doi.org\/10.1186\/1479-5876-9-136.","journal-title":"J Transl Med"},{"key":"692_CR68","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1016\/j.numecd.2013.01.006","volume":"23","author":"G Sesti","year":"2013","unstructured":"Sesti G, Fiorentino TV, Hribal ML, Sciacqua A, Perticone F. Association of hepatic insulin resistance indexes to nonalcoholic fatty liver disease and related biomarkers. Nutr Metab Cardiovasc Dis. 2013;23:1182\u20137. https:\/\/doi.org\/10.1016\/j.numecd.2013.01.006.","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"692_CR69","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1111\/hepr.12408","volume":"45","author":"Y Sumida","year":"2015","unstructured":"Sumida Y, Yonei Y, Tanaka S, Mori K, Kanemasa K, Imai S, et al. Lower levels of insulin-like growth factor-1 standard deviation score are associated with histological severity of non-alcoholic fatty liver disease. Hepatol Res. 2015;45:771\u201381. https:\/\/doi.org\/10.1111\/hepr.12408.","journal-title":"Hepatol Res"},{"key":"692_CR70","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1097\/hep.0000000000000004","volume":"77","author":"ZM Younossi","year":"2023","unstructured":"Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023;77:1335\u201347. https:\/\/doi.org\/10.1097\/hep.0000000000000004.","journal-title":"Hepatology"},{"key":"692_CR71","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1530\/eje.1.02179","volume":"155","author":"R Abs","year":"2006","unstructured":"Abs R, Feldt-Rasmussen U, Mattsson AF, Monson JP, Bengtsson BA, G\u00f3th MI, et al. Determinants of cardiovascular risk in 2589 hypopituitary GH-deficient adults - a KIMS database analysis. Eur J Endocrinol. 2006;155:79\u201390. https:\/\/doi.org\/10.1530\/eje.1.02179.","journal-title":"Eur J Endocrinol"},{"key":"692_CR72","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.3390\/children12091271","volume":"12","author":"Z Laron","year":"2025","unstructured":"Laron Z. Disabilities and handicaps of patients with Laron syndrome. Child (Basel). 2025;12:1271. https:\/\/doi.org\/10.3390\/children12091271.","journal-title":"Child (Basel)"},{"key":"692_CR73","doi-asserted-by":"publisher","DOI":"10.1016\/j.ghir.2024.101605","volume":"78","author":"Z Laron","year":"2024","unstructured":"Laron Z, Kauli R, Silbergeld A. Adult patients with Laron syndrome tend to develop the metabolic syndrome. Growth Horm IGF Res. 2024;78:101605. https:\/\/doi.org\/10.1016\/j.ghir.2024.101605.","journal-title":"Growth Horm IGF Res"},{"key":"692_CR74","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.ghir.2008.03.003","volume":"18","author":"Z Laron","year":"2008","unstructured":"Laron Z, Ginsberg S, Webb M. Nonalcoholic fatty liver in patients with Laron syndrome and GH gene deletion - preliminary report. Growth Horm IGF Res. 2008;18:434\u20138. https:\/\/doi.org\/10.1016\/j.ghir.2008.03.003.","journal-title":"Growth Horm IGF Res"},{"key":"692_CR75","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s12020-019-01982-1","volume":"65","author":"Y Yao","year":"2019","unstructured":"Yao Y, Miao X, Zhu D, Li D, Zhang Y, Song C, et al. Insulin-like growth factor-1 and non-alcoholic fatty liver disease: a systemic review and meta-analysis. Endocrine. 2019;65:227\u201337. https:\/\/doi.org\/10.1007\/s12020-019-01982-1.","journal-title":"Endocrine"},{"key":"692_CR76","doi-asserted-by":"publisher","first-page":"e520","DOI":"10.1210\/clinem\/dgaa792","volume":"106","author":"TL Stanley","year":"2021","unstructured":"Stanley TL, Fourman LT, Zheng I, McClure CM, Feldpausch MN, Torriani M, et al. Relationship of IGF-1 and IGF-Binding proteins to disease severity and glycemia in nonalcoholic fatty liver disease. J Clin Endocrinol Metab. 2021;106:e520\u201333. https:\/\/doi.org\/10.1210\/clinem\/dgaa792.","journal-title":"J Clin Endocrinol Metab"},{"key":"692_CR77","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.metabol.2019.05.001","volume":"96","author":"SA Polyzos","year":"2019","unstructured":"Polyzos SA, Perakakis N, Mantzoros CS. Fatty liver in lipodystrophy: a review with a focus on therapeutic perspectives of adiponectin and\/or leptin replacement. Metabolism. 2019;96:66\u201382. https:\/\/doi.org\/10.1016\/j.metabol.2019.05.001.","journal-title":"Metabolism"},{"key":"692_CR78","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.ghir.2012.10.001","volume":"23","author":"A Sirbu","year":"2013","unstructured":"Sirbu A, Gologan S, Arbanas T, Copaescu C, Martin S, Albu A, et al. Adiponectin, body mass index and hepatic steatosis are independently associated with IGF-I status in obese non-diabetic women. Growth Horm IGF Res. 2013;23:2\u20137. https:\/\/doi.org\/10.1016\/j.ghir.2012.10.001.","journal-title":"Growth Horm IGF Res"},{"key":"692_CR79","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.metabol.2010.09.003","volume":"60","author":"SA Polyzos","year":"2011","unstructured":"Polyzos SA, Toulis KA, Goulis DG, Zavos C, Kountouras J. Serum total adiponectin in nonalcoholic fatty liver disease: a systematic review and meta-analysis. Metabolism. 2011;60:313\u201326. https:\/\/doi.org\/10.1016\/j.metabol.2010.09.003.","journal-title":"Metabolism"},{"key":"692_CR80","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1159\/000064660","volume":"58","author":"C Groisne","year":"2002","unstructured":"Groisne C, Trivin C, Souberbielle JC, Brauner R. Factors influencing the growth hormone response to growth hormone-releasing hormone in children with idiopathic growth hormone deficiency. Horm Res. 2002;58:94\u20138. https:\/\/doi.org\/10.1159\/000064660.","journal-title":"Horm Res"},{"key":"692_CR81","first-page":"713","volume":"17","author":"A Eshraghian","year":"2014","unstructured":"Eshraghian A, Taghavi SA. Systematic review: endocrine abnormalities in patients with liver cirrhosis. Arch Iran Med. 2014;17:713\u201321.","journal-title":"Arch Iran Med"},{"key":"692_CR82","doi-asserted-by":"publisher","first-page":"2539","DOI":"10.1002\/cncr.11002","volume":"95","author":"G Mazziotti","year":"2002","unstructured":"Mazziotti G, Sorvillo F, Morisco F, Carbone A, Rotondi M, Stornaiuolo G, et al. Serum insulin-like growth factor I evaluation as a useful tool for predicting the risk of developing hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a prospective study. Cancer. 2002;95:2539\u201345. https:\/\/doi.org\/10.1002\/cncr.11002.","journal-title":"Cancer"},{"key":"692_CR83","doi-asserted-by":"publisher","DOI":"10.1093\/ejendo\/lvac014","volume":"188","author":"MC Arlien-S\u00f8borg","year":"2023","unstructured":"Arlien-S\u00f8borg MC, Madsen MA, Dal J, Krusenstjerna-Hafstr\u00f8m T, Ringgaard S, Skou N, et al. Ectopic lipid deposition and insulin resistance in patients with GH disorders before and after treatment. Eur J Endocrinol. 2023;188:lvac014. https:\/\/doi.org\/10.1093\/ejendo\/lvac014.","journal-title":"Eur J Endocrinol"},{"key":"692_CR84","doi-asserted-by":"publisher","first-page":"3420","DOI":"10.1210\/clinem\/dgaf155","volume":"110","author":"C Baumgartner","year":"2025","unstructured":"Baumgartner C, Metz M, Beghini M, Pfleger L, Tosin A, Koldyka O, et al. Growth hormone promotes hepatic triglyceride export in humans. J Clin Endocrinol Metab. 2025;110:3420\u20139. https:\/\/doi.org\/10.1210\/clinem\/dgaf155.","journal-title":"J Clin Endocrinol Metab"},{"key":"692_CR85","doi-asserted-by":"publisher","first-page":"e1542","DOI":"10.1210\/clinem\/dgad375","volume":"108","author":"LE Dichtel","year":"2023","unstructured":"Dichtel LE, Corey KE, Haines MS, Chicote ML, Lee H, Kimball A, et al. Growth hormone administration improves nonalcoholic fatty liver disease in overweight\/obesity: a randomized trial. J Clin Endocrinol Metab. 2023;108:e1542\u201350. https:\/\/doi.org\/10.1210\/clinem\/dgad375.","journal-title":"J Clin Endocrinol Metab"},{"key":"692_CR86","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.ghir.2014.07.002","volume":"24","author":"R Matsumoto","year":"2014","unstructured":"Matsumoto R, Fukuoka H, Iguchi G, Nishizawa H, Bando H, Suda K, et al. Long-term effects of growth hormone replacement therapy on liver function in adult patients with growth hormone deficiency. Growth Horm IGF Res. 2014;24:174\u20139. https:\/\/doi.org\/10.1016\/j.ghir.2014.07.002.","journal-title":"Growth Horm IGF Res"},{"key":"692_CR87","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1111\/cen.14344","volume":"94","author":"CS Pan","year":"2021","unstructured":"Pan CS, Weiss JJ, Fourman LT, Buckless C, Branch KL, Lee H, et al. Effect of Recombinant human growth hormone on liver fat content in young adults with nonalcoholic fatty liver disease. Clin Endocrinol (Oxf). 2021;94:183\u201392. https:\/\/doi.org\/10.1111\/cen.14344.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"692_CR88","doi-asserted-by":"publisher","first-page":"e821","DOI":"10.1016\/s2352-3018(19)30338-8","volume":"6","author":"TL Stanley","year":"2019","unstructured":"Stanley TL, Fourman LT, Feldpausch MN, Purdy J, Zheng I, Pan CS, et al. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV. 2019;6:e821\u201330. https:\/\/doi.org\/10.1016\/s2352-3018(19)30338-8.","journal-title":"Lancet HIV"},{"key":"692_CR89","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1507\/endocrj.EJ24-0481","volume":"72","author":"T Taguchi","year":"2025","unstructured":"Taguchi T, Ito S, Fujishima R, Shimizu N, Hagiwara W, Matoba K, et al. Hypertriglyceridemia and younger age are associated with effectiveness of growth hormone therapy on hepatic steatosis. Endocr J. 2025;72:355\u201364. https:\/\/doi.org\/10.1507\/endocrj.EJ24-0481.","journal-title":"Endocr J"},{"key":"692_CR90","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1053\/j.gastro.2006.12.024","volume":"132","author":"Y Takahashi","year":"2007","unstructured":"Takahashi Y, Iida K, Takahashi K, Yoshioka S, Fukuoka H, Takeno R, et al. Growth hormone reverses nonalcoholic steatohepatitis in a patient with adult growth hormone deficiency. Gastroenterology. 2007;132:938\u201343. https:\/\/doi.org\/10.1053\/j.gastro.2006.12.024.","journal-title":"Gastroenterology"},{"key":"692_CR91","doi-asserted-by":"publisher","first-page":"336","DOI":"10.4103\/ijem.ijem_488_23","volume":"28","author":"D Dutta","year":"2024","unstructured":"Dutta D, Nagendra L, Mohindra R, Bhattacharya S, Joshi A, Kamrul-Hasan A. Role of growth hormone therapy in metabolic-dysfunction-associated steatotic liver disease: a systematic review and meta-analysis. Indian J Endocrinol Metab. 2024;28:336\u201342. https:\/\/doi.org\/10.4103\/ijem.ijem_488_23.","journal-title":"Indian J Endocrinol Metab"},{"key":"692_CR92","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1097\/meg.0000000000002819","volume":"36","author":"I Mohamed","year":"2024","unstructured":"Mohamed I, Gautam M, Abosheaishaa H, Hussain S, Kumar K, Kotak A, et al. Growth hormone augmentation in metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis of randomized controlled trials. Eur J Gastroenterol Hepatol. 2024;36:1259\u201366. https:\/\/doi.org\/10.1097\/meg.0000000000002819.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"692_CR93","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvaf072","volume":"9","author":"O Cooper","year":"2025","unstructured":"Cooper O, Kim S. Growth hormone replacement in Craniopharyngioma: analysis of the Hypopituitary Control and Complications Study (HypoCCS). J Endocr Soc. 2025;9:bvaf072. https:\/\/doi.org\/10.1210\/jendso\/bvaf072.","journal-title":"J Endocr Soc"},{"key":"692_CR94","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1136\/gutjnl-2024-332491","volume":"73","author":"A Mantovani","year":"2024","unstructured":"Mantovani A, Csermely A, Bilson J, Borella N, Enrico S, Pecoraro B, et al. Association between primary hypothyroidism and metabolic dysfunction-associated steatotic liver disease: an updated meta-analysis. Gut. 2024;73:1554\u201361. https:\/\/doi.org\/10.1136\/gutjnl-2024-332491.","journal-title":"Gut"},{"key":"692_CR95","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1007\/s12020-024-03878-1","volume":"86","author":"K Papadimitriou","year":"2024","unstructured":"Papadimitriou K, Mousiolis AC, Mintziori G, Tarenidou C, Polyzos SA, Goulis DG. Hypogonadism and nonalcoholic fatty liver disease. Endocrine. 2024;86:28\u201347. https:\/\/doi.org\/10.1007\/s12020-024-03878-1.","journal-title":"Endocrine"},{"key":"692_CR96","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/bs.acr.2025.09.005","volume":"167","author":"E Montgomery","year":"2025","unstructured":"Montgomery E, Mitra S, Kline C, Hankinson TC. Craniopharyngioma. Adv Cancer Res. 2025;167:243\u201377. https:\/\/doi.org\/10.1016\/bs.acr.2025.09.005.","journal-title":"Adv Cancer Res"},{"key":"692_CR97","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1093\/ejendo\/lvaf244","volume":"193","author":"A B\u00e6k","year":"2025","unstructured":"B\u00e6k A, Pedersen AKN, Billeskov TB, Dollerup OL, Arlien-S\u00f8borg MC, Jessen N, et al. GH replacement therapy in adults stimulates fibroblast activation protein-\u03b1 activity. Eur J Endocrinol. 2025;193:659\u201366. https:\/\/doi.org\/10.1093\/ejendo\/lvaf244.","journal-title":"Eur J Endocrinol"},{"key":"692_CR98","doi-asserted-by":"publisher","first-page":"dgz033","DOI":"10.1210\/clinem\/dgz033","volume":"105","author":"MC Arlien-S\u00f8borg","year":"2020","unstructured":"Arlien-S\u00f8borg MC, Gr\u00f8ndahl C, B\u00e6k A, Dal J, Madsen M, H\u00f8gild ML, et al. Fibroblast activation protein is a GH target: A prospective study of patients with acromegaly before and after treatment. J Clin Endocrinol Metab. 2020;105:dgz033. https:\/\/doi.org\/10.1210\/clinem\/dgz033.","journal-title":"J Clin Endocrinol Metab"},{"key":"692_CR99","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1111\/j.1742-1241.2011.02682.x","volume":"65","author":"P Anagnostis","year":"2011","unstructured":"Anagnostis P, Efstathiadou ZA, Polyzos SA, Adamidou F, Slavakis A, Sapranidis M, et al. Acromegaly: presentation, morbidity and treatment outcomes at a single centre. Int J Clin Pract. 2011;65:896\u2013902. https:\/\/doi.org\/10.1111\/j.1742-1241.2011.02682.x.","journal-title":"Int J Clin Pract"},{"key":"692_CR100","doi-asserted-by":"publisher","first-page":"2334","DOI":"10.1210\/jc.2007-2780","volume":"93","author":"PU Freda","year":"2008","unstructured":"Freda PU, Shen W, Heymsfield SB, Reyes-Vidal CM, Geer EB, Bruce JN, et al. Lower visceral and subcutaneous but higher intermuscular adipose tissue depots in patients with growth hormone and insulin-like growth factor I excess due to acromegaly. J Clin Endocrinol Metab. 2008;93:2334\u201343. https:\/\/doi.org\/10.1210\/jc.2007-2780.","journal-title":"J Clin Endocrinol Metab"},{"key":"692_CR101","doi-asserted-by":"publisher","first-page":"2946","DOI":"10.1210\/jc.2015-1917","volume":"100","author":"CM Reyes-Vidal","year":"2015","unstructured":"Reyes-Vidal CM, Mojahed H, Shen W, Jin Z, Arias-Mendoza F, Fernandez JC, et al. Adipose tissue redistribution and ectopic lipid deposition in active acromegaly and effects of surgical treatment. J Clin Endocrinol Metab. 2015;100:2946\u201355. https:\/\/doi.org\/10.1210\/jc.2015-1917.","journal-title":"J Clin Endocrinol Metab"},{"key":"692_CR102","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvad028","volume":"7","author":"AP Kuker","year":"2023","unstructured":"Kuker AP, Shen W, Jin Z, Chen J, Bruce NJ, Freda PU. Long-term outcome of body composition, ectopic lipid, and insulin resistance changes with surgical treatment of acromegaly. J Endocr Soc. 2023;7:bvad028. https:\/\/doi.org\/10.1210\/jendso\/bvad028.","journal-title":"J Endocr Soc"},{"key":"692_CR103","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1210\/jc.2011-2681","volume":"97","author":"M Madsen","year":"2012","unstructured":"Madsen M, Krusenstjerna-Hafstr\u00f8m T, M\u00f8ller L, Christensen B, Vendelbo MH, Pedersen SB, et al. Fat content in liver and skeletal muscle changes in a reciprocal manner in patients with acromegaly during combination therapy with a somatostatin analog and a GH receptor antagonist: a randomized clinical trial. J Clin Endocrinol Metab. 2012;97:1227\u201335. https:\/\/doi.org\/10.1210\/jc.2011-2681.","journal-title":"J Clin Endocrinol Metab"},{"key":"692_CR104","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1210\/jc.2011-0179","volume":"96","author":"ME Molitch","year":"2011","unstructured":"Molitch ME, Clemmons DR, Malozowski S, Merriam GR, Vance ML. Evaluation and treatment of adult growth hormone deficiency: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2011;96:1587\u2013609. https:\/\/doi.org\/10.1210\/jc.2011-0179.","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Current Obesity Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13679-026-00692-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13679-026-00692-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13679-026-00692-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:27:44Z","timestamp":1781634464000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13679-026-00692-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,19]]},"references-count":104,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["692"],"URL":"https:\/\/doi.org\/10.1007\/s13679-026-00692-w","relation":{},"ISSN":["2162-4968"],"issn-type":[{"value":"2162-4968","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,19]]},"assertion":[{"value":"3 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human subjects performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights and informed consent"}},{"value":"All figures and tables are original and were developed specifically for this article; therefore, no permission to reproduce is required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Originality of figures and tables"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10"}}